Novavax Management
Management criteria checks 3/4
Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 2.92 years. total yearly compensation is $5.09M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 0.084% of the company’s shares, worth $898.29K. The average tenure of the management team and the board of directors is 2.8 years and 5 years respectively.
Key information
John Jacobs
Chief executive officer
US$5.1m
Total compensation
| CEO salary percentage | 14.79% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.8yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Milestones Over Sales: The Sanofi Partnership Now Drives Novavax's Outlook
Nov 26Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth
May 20
Novavax: Grandiose Ambitions, Smart Strategy, But FDA Decision Adds To Challenges
Apr 28
Sanofi Partnership And Pipeline Programs Will Expand Future Markets
Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer
Apr 11The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%
Apr 02Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 12Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Jan 16Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Dec 17Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Nov 15Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Nov 13Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Nov 01Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Oct 31Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Sep 01Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Aug 14Novavax: Staying Long Despite Coming Up Short In Q2
Aug 13Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Jul 26Novavax: New Chapter, Questions Remain
Jun 20Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement
May 14Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 13Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely
May 07Novavax: Another Day Older And Deeper In
Mar 02Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Mar 02Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Mar 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$342m |
| Jun 30 2025 | n/a | n/a | US$423m |
| Mar 31 2025 | n/a | n/a | US$479m |
| Dec 31 2024 | US$5m | US$753k | -US$187m |
| Sep 30 2024 | n/a | n/a | -US$285m |
| Jun 30 2024 | n/a | n/a | -US$294m |
| Mar 31 2024 | n/a | n/a | -US$399m |
| Dec 31 2023 | US$7m | US$663k | -US$545m |
Compensation vs Market: John's total compensation ($USD5.09M) is above average for companies of similar size in the US market ($USD3.46M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Jacobs (58 yo)
Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.9yrs | US$5.09m | 0.084% $ 898.3k | |
| Executive VP | 4.3yrs | US$1.83m | 0.044% $ 470.6k | |
| Executive VP | 2yrs | US$1.06m | 0.020% $ 210.1k | |
| Executive VP & Chief Strategy Officer | 2.8yrs | US$1.64m | 0.035% $ 377.6k | |
| Executive VP & COO | 2.9yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Associate Director of Investor & Public Relations | 7.7yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | 2.4yrs | no data | no data | |
| Executive VP | 3.9yrs | no data | no data | |
| Executive VP & Chief Regulatory Officer | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer | 1.1yrs | no data | no data | |
| Executive VP and Head of Research & Development | 1.1yrs | no data | 0.0050% $ 53.9k |
Experienced Management: NVAX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.9yrs | US$5.09m | 0.084% $ 898.3k | |
| Independent Director | 5.5yrs | US$468.61k | 0.037% $ 400.0k | |
| Independent Director | 15.9yrs | US$470.61k | 0.033% $ 357.0k | |
| Independent Chairperson | 5yrs | US$466.08k | 0.016% $ 168.1k | |
| Independent Director | 5.2yrs | US$453.43k | 0.018% $ 189.3k | |
| Independent Director | 7.1yrs | US$456.11k | 0.015% $ 165.5k | |
| Independent Director | 3.2yrs | US$476.43k | 0.018% $ 187.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: NVAX's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/14 10:18 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novavax, Inc. is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| George Zavoico | B. Riley Securities, Inc. |